Medical Countermeasures

Medical Countermeasures

  • Six radiation countermeasures for ARS have U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) status. These are 5-androstenediol (5-AED, Neumune), genistein (BIO300), Ex-Rad®, Entolimod (CBLB502), OrbeShield™, and HemaMax™ (rhIL-12). AFRRI has been involved in the development of five of these seven agents.
  • Both 5-AED and genistein conceived as countermeasures were initially developed at AFRRI.
  • Ex-Rad® and CBLB502 though initiated at private companies, AFRRI collaborated at early stages.
  • AFRRI performed some of the earliest work on cytokines and growth factors as radiation countermeasures. This led to inclusion of Neupogen® in the Strategic National Stockpile.
  • AFRRI continues an intensive program on identification and development of radiation countermeasures to be used by military and civilian personnel. This work depends on studies aimed at understanding the mechanisms of radiation injury and countermeasure efficacy.
  • AFRRI has been funded for initial development of countermeasure candidates. Advanced development is carried out by companies or other government agencies after AFRRI’s initial screening.